8-K: Interpace Biosciences Reports Strong 2025 Revenue, Targets Nasdaq Uplisting

Interpace Biosciences announced preliminary 2025 thyroid testing revenue growth of 21%, initiated 2026 guidance, converted all preferred stock, and plans a Nasdaq uplisting.

Summary

• Preliminary unaudited 2025 revenue from continuing operations (thyroid testing) was approximately $38-39 million.
• Thyroid testing revenue specifically was $34-35 million, representing approximately 21% growth over 2024.
• The PancraGEN test was discontinued in early May 2025, making thyroid testing 100% of current revenue.
• Initial full-year 2026 revenue guidance is approximately $40 million, entirely from thyroid testing, representing about 16% growth over 2025.
• All outstanding Series C Preferred Stock has been converted into approximately 23,267,327 shares of common stock.
• Pro forma basic shares outstanding total approximately 27.7 million shares.
• 1315 Capital owns approximately 34% (9,405,941 shares) and Ampersand owns approximately 50% (13,861,386 shares) of outstanding common stock post-conversion.
• The company has a debt-free balance sheet and positive Net Income and EBITDA operations.
• Interpace intends to seek an uplisting on the Nasdaq Stock Market in 2026.

Sentiment

Score: 8

Explanation: The filing presents a very positive outlook with strong revenue growth in its core business, a significantly simplified and strengthened balance sheet (debt-free, no preferred stock), and clear strategic plans for market expansion (Nasdaq uplisting) and operational improvement. The risks mentioned are standard forward-looking statement disclaimers, and the discontinuation of PancraGEN is framed as a strategic focus rather than a setback.

Positives

• Preliminary 2025 thyroid testing revenue grew approximately 21% over the prior year.
• Initial 2026 guidance projects 16% growth in thyroid testing revenue.
• All preferred stock has been converted to common stock, greatly simplifying the capital structure.
• The company has a debt-free balance sheet.
• Operations are generating positive Net Income and EBITDA.
• Plans to seek an uplisting on the Nasdaq Stock Market in 2026, which could enable more investors to participate in growth.
• Focused investments are planned for sales acceleration, revitalized commercial research and development, and ongoing lab automation.

Negatives

• The PancraGEN test was discontinued in early May 2025, reducing product diversification.
• Financial results for 2025 are preliminary and unaudited, subject to audit review and adjustments.
• No assurance can be given that the Nasdaq uplisting will be successfully achieved.

Risks

• Estimates of future revenue, net income, and adjusted EBITDA may prove to be materially inaccurate.
• Preliminary unaudited financial results are subject to audit review and adjustments.
• Prior history of operating losses.
• Ability to adequately finance its business.
• Dependence on sales and reimbursements from clinical services.
• Ability to retain or secure reimbursement, including reliance on third parties to process and transmit claims to payers.
• Adverse impact of any delay, data loss, or other disruption in processing or transmitting claims.
• Revenue recognition is based in part on estimates for future collections, which may prove incorrect.
• General risks detailed from time to time in the Company's Annual Report on Form 10-K, Current Reports on Form 8-K, and Quarterly Reports on Form 10-Q.

Future Outlook

The company projects approximately $40 million in revenue for full-year 2026, entirely from thyroid testing, representing 16% growth over 2025. Interpace also intends to seek an uplisting to the Nasdaq Stock Market in 2026, which is expected to enable more investors to participate in future growth and pave the way for focused investments in sales acceleration, revitalized commercial R&D, and ongoing lab automation.

Management Comments

• "This conversion is a pivotal milestone in our capital structure journey. In addition to paying off 100% of the Company’s outstanding debt in December, Interpace has now retired all shares of preferred stock, greatly simplifying the capital structure as we focus on scaling a profitable, thyroid-focused diagnostics business." Tom Burnell, Chairman, President & CEO.
• "We believe that Interpace is in a strong financial position, and that uplisting to the Nasdaq Market will enable more investors to participate in the growth we expect going forward. This action paves the way for focused investments in sales acceleration, revitalized commercial research and development plans, and ongoing lab automation." Chris McCarthy, Chief Financial Officer & Chief Operating Officer.

Industry Context

This announcement positions Interpace Biosciences as a specialized player in the personalized medicine and molecular diagnostics sector, specifically focusing on thyroid cancer. The move to simplify its capital structure and seek a Nasdaq uplisting aligns with a trend among growing diagnostic companies to enhance visibility and access to broader capital markets. The focus on thyroid testing, leveraging technologies like next-generation sequencing (ThyGeNEXT) and microRNA profiling (ThyraMIRv2), reflects the industry's shift towards more precise and targeted diagnostic solutions for improved patient management.

Stakeholder Impact

• Shareholders: Significant positive impact due to simplified capital structure, debt-free status, positive operational metrics, and potential for increased liquidity and investor interest from a Nasdaq uplisting.
• Employees: Potential for growth and investment in R&D and lab automation could lead to new opportunities and stability.
• Customers: Continued focus on thyroid testing and investments in R&D and lab automation suggest ongoing commitment to improving diagnostic services.
• Creditors: Positive impact from the company becoming debt-free.

Next Steps

• Seek an uplisting to the Nasdaq Stock Market in 2026.
• Focused investments in sales acceleration.
• Revitalized commercial research and development plans.
• Ongoing lab automation.

Key Dates

Recommendation

The company has demonstrated strong preliminary revenue growth in its core thyroid testing business, achieved a debt-free balance sheet, and simplified its capital structure by converting all preferred stock. The strategic intent to uplist to Nasdaq, coupled with positive operational metrics (Net Income and EBITDA), suggests a company poised for increased visibility, liquidity, and further growth. These factors collectively present a compelling investment case for a seasoned investor.

Keywords

Interpace Biosciences, IDXG, thyroid testing, molecular diagnostics, cancer diagnostics, Nasdaq uplisting, capital structure, revenue growth, preferred stock conversion, debt-free, personalized medicine, ThyGeNEXT, ThyraMIRv2